For research use only
| Cat No. | ABC-TC0384 |
| Product Type | Human Gastric Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lymph Node |
| Disease | Gastric Cancer |
| Product Code | HGC 27; HGC27 |
HGC-27 Cell Line is a gastric cancer cell model used for studying tumor progression, drug resistance, and novel therapeutic targets in oncology research.
HGC-27 is a human gastric adenocarcinoma cell line derived in 1975 from the metastatic lymph node of a 37-year-old male patient with poorly differentiated gastric adenocarcinoma. These cells exhibit epithelial-like morphology and adhere firmly in culture. They display a rapid doubling time of approximately 17 hours. Chromosomal analysis reveals aneuploid chromosomal instability with a modal chromosome number ranging from 109 to 110. This cell line demonstrates strong tumorigenic potential in xenograft models and is known for its robust engraftment efficiency in preclinical studies. HGC-27 secretes mucins, making it a valuable model for investigating mucin-related pathobiology. It is widely used to investigate gastric cancer progression, cell proliferation, migration, invasion, and cancer stem-like properties.
| Product Code | HGC 27; HGC27 |
| Species | Human |
| Cat.No | ABC-TC0384 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lymph Node |
| Disease | Gastric Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Gastric Cancer Cell Lines |
HGC-27 cells are extensively used in human gastric cancer research to study critical cellular processes such as proliferation, migration, and invasion. Their aggressive phenotype and mucin-secreting properties make them an ideal platform for evaluating anticancer drugs and understanding the molecular mechanisms driving tumor progression. This cell line provides a versatile and clinically relevant model for preclinical drug screening and the development of targeted therapies for gastric cancer, ultimately supporting efforts to identify potential therapeutic strategies against this aggressive malignancy.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
